Suppr超能文献

在饮食诱导的非酒精性脂肪性肝病小鼠模型中,对乙酰氨基酚诱导的肝损伤没有易感性增加。

Absence of Increased Susceptibility to Acetaminophen-Induced Liver Injury in a Diet-Induced NAFLD Mouse Model.

机构信息

Comparative and Molecular Pathogenesis Branch, Division of Translational Toxicology, National Institute of Environmental Health Services, Research Triangle Park, North Carolina, USA.

Osaka Metropolitan University, Osaka, Japan.

出版信息

Toxicol Pathol. 2023 Apr;51(3):112-125. doi: 10.1177/01926233231171101. Epub 2023 May 9.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease and its influence on drug-induced liver injury (DILI) is not fully understood. We investigated whether NAFLD can influence acetaminophen (APAP [N-acetyl-p-aminophenol])-induced hepatotoxicity in a diet-induced obese (DIO) mouse model of NAFLD. The male C57BL/6NTac DIO mice, fed a high-fat diet for more than 12 weeks, developed obesity, hyperinsulinemia, impaired glucose tolerance, and hepatomegaly with hepatic steatosis, similar to human NAFLD. In the acute toxicity study after a single dose of APAP (150 mg/kg), compared with control lean mice, the DIO mice had decreased serum transaminase levels and less severe hepatocellular injury. The DIO mice also had altered expression of genes related to APAP metabolism. Chronic APAP exposure for 26 weeks did not predispose the DIO mice with NAFLD to more severe hepatotoxicity compared with the lean mice. These results suggested that the C57BL/6NTac DIO mouse model appears to be more tolerant to APAP-induced hepatotoxicity than lean mice, potentially related to altered xenobiotic metabolizing capacity in the fatty liver. Further mechanistic studies with APAP and other drugs in NAFLD animal models are necessary to investigate the mechanism of altered susceptibility to intrinsic DILI in some human NAFLD patients.

摘要

非酒精性脂肪性肝病 (NAFLD) 是一种常见的慢性肝脏疾病,但其对药物性肝损伤 (DILI) 的影响尚不完全清楚。我们研究了非酒精性脂肪性肝病 (NAFLD) 是否会影响饮食诱导肥胖 (DIO) 小鼠模型中的对乙酰氨基酚 (APAP[N-乙酰-p-氨基酚]) 诱导的肝毒性。雄性 C57BL/6NTac DIO 小鼠,给予高脂肪饮食超过 12 周,会发展为肥胖、高胰岛素血症、葡萄糖耐量受损和肝肿大伴肝脂肪变性,类似于人类的 NAFLD。在单次给予 APAP(150mg/kg)后的急性毒性研究中,与对照瘦小鼠相比,DIO 小鼠的血清转氨酶水平降低,肝细胞损伤较轻。DIO 小鼠中与 APAP 代谢相关的基因表达也发生了改变。与瘦小鼠相比,慢性 26 周 APAP 暴露并未使患有 NAFLD 的 DIO 小鼠更容易发生更严重的肝毒性。这些结果表明,C57BL/6NTac DIO 肥胖小鼠模型似乎比瘦小鼠对 APAP 诱导的肝毒性更耐受,这可能与脂肪肝中外源物质代谢能力的改变有关。在 NAFLD 动物模型中进一步研究 APAP 和其他药物的机制,对于研究某些人类 NAFLD 患者内在 DILI 易感性改变的机制是必要的。

相似文献

7
Acetaminophen-Induced Liver Damage in Hepatic Steatosis.在肝脂肪变性中,对乙酰氨基酚引起的肝损伤。
Clin Pharmacol Ther. 2020 May;107(5):1068-1081. doi: 10.1002/cpt.1701. Epub 2019 Dec 6.

引用本文的文献

2
Hepatic Bile Acid Transporters and Drug-induced Hepatotoxicity.肝脏胆汁酸转运体与药物性肝损伤
Toxicol Pathol. 2023 Oct;51(7-8):405-413. doi: 10.1177/01926233231212255. Epub 2023 Nov 20.

本文引用的文献

4
Acetaminophen-Induced Liver Damage in Hepatic Steatosis.在肝脂肪变性中,对乙酰氨基酚引起的肝损伤。
Clin Pharmacol Ther. 2020 May;107(5):1068-1081. doi: 10.1002/cpt.1701. Epub 2019 Dec 6.
5
Drug-induced liver injury.药物性肝损伤。
Nat Rev Dis Primers. 2019 Aug 22;5(1):58. doi: 10.1038/s41572-019-0105-0.
8
EASL Clinical Practice Guidelines: Drug-induced liver injury.EASL 临床实践指南:药物性肝损伤。
J Hepatol. 2019 Jun;70(6):1222-1261. doi: 10.1016/j.jhep.2019.02.014. Epub 2019 Mar 27.
9
Burden of liver diseases in the world.世界范围内的肝脏疾病负担。
J Hepatol. 2019 Jan;70(1):151-171. doi: 10.1016/j.jhep.2018.09.014. Epub 2018 Sep 26.
10
Animal models of NAFLD from a hepatologist's point of view.从肝病学家的角度看非酒精性脂肪性肝病的动物模型。
Biochim Biophys Acta Mol Basis Dis. 2019 May 1;1865(5):943-953. doi: 10.1016/j.bbadis.2018.06.023. Epub 2018 Jul 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验